Gilead Sciences (GILD) Finished Goods (2009 - 2015)
Gilead Sciences' (GILD) quarterly Finished Goods came in at $852.0 million in Q4 2015, up 82.83% on a YoY basis from $466.0 million in Q4 2014, and up 82.83% quarter-over-quarter from $466.0 million in Q4 2014.
Analysis
Gilead Sciences (GILD) Finished Goods (2009 - 2015) Analysis & Trends
Gilead Sciences (GILD) has reported Finished Goods for 7 consecutive years, with $852.0 million the latest figure, recorded in Q4 2015.
- For the quarter ending Q4 2015, Finished Goods rose 82.83% year-over-year to $852.0 million; the trailing twelve-month figure through Dec 2015 stood at $852.0 million (up 82.83% YoY), and the FY2015 full-year result was $852.0 million, up 82.83% from the prior year.
- Finished Goods grew to $852.0 million in Q4 2015 per GILD's latest filing, from $466.0 million in the prior quarter.
- Across five years, Finished Goods topped out at $852.0 million in Q4 2015 and bottomed at $225.9 million in Q4 2011.
- Historically, Finished Goods has averaged $487.3 million across 5 years, with a median of $466.0 million in 2014.
- The sharpest annual moves came in 2011 and 2012: Finished Goods slumped 33.79% in 2011, then surged 147.9% in 2012.
- Over 5 years, Finished Goods stood at $225.9 million in 2011, then soared by 147.9% to $559.9 million in 2012, then gained by 5.99% to $593.4 million in 2013, then slipped by 21.47% to $466.0 million in 2014, then surged by 82.83% to $852.0 million in 2015.
- According to Business Quant data, Finished Goods over the past three periods registered $852.0 million, $466.0 million, and $560.0 million for Q4 2015, Q4 2014, and Q2 2014 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2015 | 852.00 Mn |
| Dec 31, 2014 | 466.00 Mn |
| Jun 30, 2014 | 559.98 Mn |
| Dec 31, 2013 | 593.44 Mn |
| Dec 31, 2012 | 559.91 Mn |
| Dec 31, 2011 | 225.86 Mn |
| Sep 30, 2011 | 295.79 Mn |
| Jun 30, 2011 | 384.72 Mn |
| Mar 31, 2011 | 448.43 Mn |
| Dec 31, 2010 | 341.14 Mn |
| Sep 30, 2010 | 439.32 Mn |
| Dec 31, 2009 | 326.15 Mn |